Showing posts with label methicillin-resistant Staphylococcus aureus (MRSA). Show all posts
Showing posts with label methicillin-resistant Staphylococcus aureus (MRSA). Show all posts

Saturday, October 17, 2009

A comparison of linezolid with glycopeptides in severe MRSA pneumonia.

A comparison of linezolid with glycopeptides in severe MRSA pneumonia.


Division of Pulmonary and Critical Care Medicine, University of Connecticut Health Center, Farmington, CT 06030-1225, USA. jafar_jamil@hotmail.com

Evaluation of: Luna CM, Bruno DA, GarcĂ­a-Morato J et al. Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest 135(6), 1564-1571 (2009). Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major pathogen in nosocomial infections and accounts for a large proportion of nosocomial pneumonia. However, there are limited antibiotics available for the treatment of this serious and potentially lethal infection. Until recently, the only effective antibiotic was vancomycin, but the oxazolidinones, such as linezolid, have been shown to be a valuable addition to the arsenal of antimicrobial agents that can be used for MRSA pneumonia.

Clinical trials have been conducted to compare vancomycin and linezolid head-to-head in pneumonia and, in post hoc subgroup analyses, showed that linezolid use was associated with improved survival. The ensuing debate over these results was dominated by two opinions; there were those who speculated on the mechanism by which linezolid achieved this benefit, namely attributing it to pharmacodynamics and pharmacokinetics, and others who criticized the methodology of the studies and questioned the validity of the results altogether.

This study by Luna and colleagues was designed with several goals in mind. The first was to attempt to generate an animal model of MRSA pneumonia in piglets by duplicating techniques used in animal models of Gram-negative pneumonia. Then they studied the effect of three antibiotics (vancomycin, linezolid and teicoplanin) on outcomes in the same model, while simultaneously measuring antibiotic levels in the serum, bronchoalveolar lavage fluid and lung tissue, in an attempt to attribute differences in survival to pharmacological properties of the drugs used.

Their results showed a survival benefit only for linezolid, despite the fact that all three antibiotics had levels above MIC in all the compartments sampled, leading them to speculate that linezolid may have improved outcomes by mechanisms not directly related to its antimicrobial actions.

Expert Reviews

Tuesday, February 26, 2008

Prophylactic antibiotics given within 24 hours of surgery, compared with antibiotics given for 72 hours perioperatively increased rate of MRSA

Prophylactic antibiotics given within 24 hours of surgery, compared with antibiotics given for 72 hours perioperatively, increased the rate of methicillin-resistant Staphylococcus aureus isolated from surgical site infections

J Infect Chemother. 2008 Feb

Kusachi S, Sumiyama Y, Nagao J, Arima Y, Yoshida Y, Tanaka H, Nakamura Y, Saida Y, Watanabe M, Watanabe R, Sato J.Third Department of Surgery, Toho University Ohashi Medical Center Hospital, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan, kusachi@med.toho-u.ac.jp.

The purpose of this research was to find which method better prevented MRSA isolation from postoperative infection sites: the administration of postoperative infection control agents within 72 h of surgery, including the day of surgery, or the administration of these agents within 24 h of surgery. More than 3000 patients who underwent elective surgery of the digestive system were studied. Cefazolin or cefotiam was used as the prophylactic antibiotic. The number of patients, sex, age, clinical stage, incidence of surgical site infection (SSI), isolated bacteria, distal pancreatectomy with or without gastrectomy, the rate of laparoscopic surgery, and the rate of abdominoperineal resection (APR) were examined in a prospective controlled study over three time periods. There were no significant differences in the demographics of patients in the three periods. The duration of antibiotic administration was 96.1 +/- 11.2 h in period A, 18.2 +/- 2.7 h in period B, and 66.9 +/- 11.1 hours in period C (P less then 0.05). There was no significant difference in the incidence of SSI in the three periods. Methicillin-resistant Staphylococcus aureus (MRSA) was isolated from the infectious site in 0.47% of patients in period A, and from 2.1% and 0.34% of patients in periods B and C, respectively, and the incidence of MRSA was significantly higher in period B as compared with periods A and C. The isolation rates of MRSA and methicillin-sensitive S. aureus (MSSA) were both significantly higher in period B patients. We concluded that the administration of prophylactic antibiotics within 24 h of surgery increased the rate of isolation of MRSA.


SpringerLink

Saturday, January 19, 2008

Reducing methicillin-resistant Staphylococcus aureus (MRSA) infections

Reducing methicillin-resistant Staphylococcus aureus (MRSA) infections

Jt Comm J Qual Patient Saf. 2007 Dec
Griffin FA.
5 Million Lives Campaign, Institute for Healthcare Improvement, Cambridge, Massachusetts, USA
fgriffin@ihi.org

BACKGROUND: Hospital-acquired infections from methicillin-resistant Staphylococcus aureus (MRSA) now account for more than 60% of S. aureus infections in intensive care patients reported to the Centers for Disease Control and Prevention (CDC). Media stories have raised the profile of this problem, and several states have moved toward legislative action regarding screening of hospital patients or mandatory reporting of infections. Guidelines from clinical expert organizations, including the CDC, the Association for Professionals in Infection Control and Epidemiology (APIC), and the Society for Healthcare Epidemiology of America (SHEA), recommend the use of basic prevention practices to avoid transmission in the hospital setting, yet concerns persist that compliance with these practices is neither consistent nor reliable.

INTERVENTION: The campaign's MRSA intervention recommends five key components of care. These are not intended to be an all-inclusive list but rather have been recommended by experts as the minimum necessary components:

(1) hand hygiene
(2) decontamination of the environment and equipment
(3) active surveillance
(4) contact precautions for infected and colonized patients, and
(5) device bundles (central line bundle and ventilator bundle).

CONCLUSION: The IHI's 5 Million Lives Campaign considers all hospital-acquired infections as harm to patients, and reduction of MRSA is one of the areas of focus.

PMID: 18200897 [PubMed - in process]